,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-12-10 06:41:00,What's a six-letter word that's guaranteed to make investors happy?,0.13041749596595764,0.05760933458805084,0.8119732141494751,neutral,0.0728081613779068
1,2017-12-10 06:41:00,Growth.,0.30071279406547546,0.018309839069843292,0.6809773445129395,neutral,0.28240296244621277
2,2017-12-10 06:41:00,"While growth comes in several flavors, they're all interrelated.",0.10380320250988007,0.006055084522813559,0.8901416659355164,neutral,0.09774811565876007
3,2017-12-10 06:41:00,"Growth in revenue helps make earnings growth possible, and earnings growth tends to drive stock prices higher.",0.9179677963256836,0.017258595675230026,0.06477369368076324,positive,0.9007092118263245
4,2017-12-10 06:41:00,There are lots of growth stocks on the market.,0.19810771942138672,0.009998566471040249,0.791893720626831,neutral,0.1881091594696045
5,2017-12-10 06:41:00,Which rank among the best?,0.10804136842489243,0.03832370042800903,0.8536348938941956,neutral,0.06971766799688339
6,2017-12-10 06:41:00,"I'd put Ligand Pharmaceuticals (NASDAQ: LGND) , Veeva Systems (NYSE: VEEV) , and Vertex Pharmaceuticals (NASDAQ: VRTX) high on the list.",0.0855703353881836,0.006647810805588961,0.9077818393707275,neutral,0.07892252504825592
7,2017-12-10 06:41:00,Here's why these are three growth stocks I'd buy right now.,0.03629700839519501,0.006818035617470741,0.9568849802017212,neutral,0.029478972777724266
8,2017-12-10 06:41:00,Ligand Pharmaceuticals' primary focus is on technologies that help other drugmakers discover and develop medicines more effectively.,0.2581782639026642,0.006468822248280048,0.7353528738021851,neutral,0.2517094314098358
9,2017-12-10 06:41:00,The two most important such technologies in Ligand's product lineup are Captisol and OmniAb.,0.15878534317016602,0.0059021469205617905,0.83531254529953,neutral,0.15288320183753967
10,2017-12-10 06:41:00,"Captisol is a modified chemical structure that helps improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).",0.2564128637313843,0.006740756798535585,0.7368463277816772,neutral,0.24967209994792938
11,2017-12-10 06:41:00,The OmniAb platform consists of several fully human antibodies that help improve manufacturability and therapeutic efficacy as well as reduce immunogenicity for drugs in development.,0.6571875214576721,0.011248724535107613,0.3315637707710266,positive,0.6459388136863708
12,2017-12-10 06:41:00,What I really like about Ligand's business model is the diversification it brings.,0.5306541323661804,0.008972513489425182,0.4603733420372009,positive,0.5216816067695618
13,2017-12-10 06:41:00,"Thirteen products are already on the market that use the company's platforms, most notably multiple myeloma drug Kyprolis and bone marrow stimulant Promacta.",0.14713893830776215,0.0055262017995119095,0.8473348021507263,neutral,0.14161273837089539
14,2017-12-10 06:41:00,"But there are dozens of other programs in Ligand's pipeline, including two currently awaiting approval and eight in late-stage development.",0.1190236508846283,0.00816792156547308,0.8728083968162537,neutral,0.11085572838783264
15,2017-12-10 06:41:00,Analysts project that Ligand will grow earnings by more than 27% annually over the next five years.,0.9541723132133484,0.016709059476852417,0.029118578881025314,positive,0.9374632835388184
16,2017-12-10 06:41:00,"With its robust pipeline, that level of growth seems attainable.",0.9115190505981445,0.014554610475897789,0.07392631471157074,positive,0.896964430809021
17,2017-12-10 06:41:00,"While the stock is up more than 25% year to date, a recent pullback presents a good buying opportunity, in my view.",0.9011721611022949,0.017214903607964516,0.08161289244890213,positive,0.8839572668075562
18,2017-12-10 06:41:00,Veeva Systems is essentially a Salesforce.com (NYSE: CRM) for the life sciences industry.,0.013222751207649708,0.008653677999973297,0.9781236052513123,neutral,0.004569073207676411
19,2017-12-10 06:41:00,"In fact, Veeva uses Salesforce's platform for some of the cloud-based customer relationship management (CRM) applications that it markets.",0.06897830218076706,0.00479194987565279,0.92622971534729,neutral,0.06418634951114655
20,2017-12-10 06:41:00,"Although Veeva has grown rapidly over the last few years, there remains a tremendous opportunity for the company in its core life sciences market.",0.8627492189407349,0.012545960023999214,0.12470480054616928,positive,0.850203275680542
21,2017-12-10 06:41:00,Veeva has tapped less than 5% of the potential market.,0.01732398010790348,0.3401815593242645,0.6424944400787354,neutral,-0.3228575885295868
22,2017-12-10 06:41:00,The company also continues to roll out new products that are attractive to existing customers.,0.8065245151519775,0.010451115667819977,0.18302445113658905,positive,0.7960733771324158
23,2017-12-10 06:41:00,Another big plus for Veeva is that it's expanding beyond life sciences .,0.7038707733154297,0.011013110168278217,0.28511613607406616,positive,0.6928576827049255
24,2017-12-10 06:41:00,Veeva landed a major consumer packaged goods customer earlier this year and hopes to gain even more traction in industries outside of its core market in the future.,0.9214745759963989,0.015497291460633278,0.06302814930677414,positive,0.9059773087501526
25,2017-12-10 06:41:00,Can Veeva keep up its fast-and-furious growth rate that has led to the stock soaring more than 40% so far in 2017?,0.9310760498046875,0.02281537838280201,0.04610855504870415,positive,0.9082606434822083
26,2017-12-10 06:41:00,Probably not.,0.13998520374298096,0.297277569770813,0.562737226486206,neutral,-0.15729236602783203
27,2017-12-10 06:41:00,"However, the consensus among Wall Street analysts is that the company will grow earnings by close to 22% annually in the coming years.",0.9501076936721802,0.01617545820772648,0.033716846257448196,positive,0.9339322447776794
28,2017-12-10 06:41:00,"Vertex Pharmaceuticals has made a name for itself in treating cystic fibrosis, a relatively rare genetic disease that can cause damage to the lungs and the digestive system.",0.767744243144989,0.013017448596656322,0.21923828125,positive,0.754726767539978
29,2017-12-10 06:41:00,The company has two CF products on the market -- Kalydeco and Orkambi.,0.05896351858973503,0.006421052385121584,0.934615433216095,neutral,0.052542466670274734
30,2017-12-10 06:41:00,Vertex withdrew hepatitis C drug Incivek from the U.S. market a few years ago in the face of new therapies that cured the disease.,0.0672835186123848,0.6934677362442017,0.23924881219863892,negative,-0.6261842250823975
31,2017-12-10 06:41:00,"While sales for Kalydeco and Orkambi continue to increase, the real promise for Vertex comes from its pipeline.",0.9106811285018921,0.01275025587528944,0.07656867057085037,positive,0.8979308605194092
32,2017-12-10 06:41:00,"The company expects an approval decision from the Food and Drug Administration on a combination of tezecaftor and ivacaftor (Kalydeco) in treating CF by Feb. 28, 2018.",0.6305278539657593,0.018637966364622116,0.3508342206478119,positive,0.6118898987770081
33,2017-12-10 06:41:00,Vertex also will initiate late-stage studies for triple-drug combinations for treating CF early next year.,0.4075356125831604,0.009705695323646069,0.5827587246894836,neutral,0.39782992005348206
34,2017-12-10 06:41:00,I expect these more powerful therapies will significantly expand the market for Vertex.,0.9225092530250549,0.013299152255058289,0.06419152021408081,positive,0.9092100858688354
35,2017-12-10 06:41:00,Analysts agree with this positive outlook.,0.890838623046875,0.024214569479227066,0.08494678139686584,positive,0.8666240572929382
36,2017-12-10 06:41:00,The average analysts' estimate for Vertex's annual earnings growth over the next five years is a whopping 65%.,0.4335212707519531,0.018980955705046654,0.5474977493286133,neutral,0.4145403206348419
37,2017-12-10 06:41:00,It's not surprising that the stock is up close to 90% year to date.,0.9146327972412109,0.0164853073656559,0.06888182461261749,positive,0.898147463798523
38,2017-12-10 06:41:00,You've probably figured out which of these three stocks is my pick as the best of the group.,0.17493599653244019,0.010973489843308926,0.8140904903411865,neutral,0.16396251320838928
39,2017-12-10 06:41:00,I like Ligand's diverse pipeline.,0.34810829162597656,0.0075621651485562325,0.6443294882774353,neutral,0.3405461311340332
40,2017-12-10 06:41:00,I think Veeva Systems has a great moat and plenty of room to run.,0.5176922678947449,0.009626944549381733,0.4726807177066803,positive,0.5080653429031372
41,2017-12-10 06:41:00,But it's hard to beat the growth prospects for Vertex.,0.044728733599185944,0.040086884051561356,0.9151843190193176,neutral,0.004641849547624588
42,2017-12-10 06:41:00,The company has a nice head start over other potential rivals in the CF market.,0.8846583366394043,0.016884341835975647,0.09845732152462006,positive,0.8677740097045898
43,2017-12-10 06:41:00,Vertex is also looking at exploring treatments for other genetic diseases.,0.1811702847480774,0.006494234781712294,0.8123354315757751,neutral,0.1746760457754135
44,2017-12-10 06:41:00,Vertex ranks as one of my five favorite biotechs on the market right now.,0.16485777497291565,0.00758607592433691,0.8275561332702637,neutral,0.15727169811725616
45,2017-12-10 06:41:00,"Like I said earlier, growth is guaranteed to make investors happy.",0.6568792462348938,0.014355160295963287,0.3287656009197235,positive,0.6425240635871887
46,2017-12-10 06:41:00,"10 stocks we like better than Vertex Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.15752483904361725,0.020843204110860825,0.8216320276260376,neutral,0.13668163120746613
47,2017-12-10 06:41:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.",0.46925464272499084,0.07301506400108337,0.4577302634716034,positive,0.39623957872390747
48,2017-12-10 06:41:00,"*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them!",0.22105975449085236,0.012158204801380634,0.7667820453643799,neutral,0.2089015543460846
49,2017-12-10 06:41:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
50,2017-12-10 06:41:00,Click here to learn about these picks!,0.0694708302617073,0.055800698697566986,0.8747285008430481,neutral,0.01367013156414032
51,2017-12-10 06:41:00,Keith Speights has no position in any of the stocks mentioned.,0.009128669276833534,0.045183293521404266,0.9456880688667297,neutral,-0.03605462610721588
52,2017-12-10 06:41:00,The Motley Fool owns shares of and recommends Veeva Systems.,0.034477271139621735,0.013045232743024826,0.9524774551391602,neutral,0.02143203839659691
53,2017-12-10 06:41:00,The Motley Fool recommends Salesforce.com and Vertex Pharmaceuticals.,0.019044319167733192,0.035506390035152435,0.9454493522644043,neutral,-0.016462070867419243
54,2017-12-10 06:41:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
55,2017-12-10 06:41:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
